Why Janssen signed a $2B+ deal with Boston-Paris biotech Nanobiotix

A French biotech with a U.S. headquarters in Cambridge has inked a licensing agreement worth well over $2 billion with Johnson& Johnson Inc.

Source: bizjournals.com Health Care:Biotechnology headlines - July 10, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news